Basal cell carcinoma
☆ AI Dermatology — Free Service
A cikin sakamakon Stiftung Warentest na 2022 daga Jamus, gamsuwar mabukaci tare da ModelDerm ya ɗan yi ƙasa kaɗan fiye da biyan shawarwarin telemedicine.
A cikin sakamakon Stiftung Warentest na 2022 daga Jamus, gamsuwar mabukaci tare da ModelDerm ya ɗan yi ƙasa kaɗan fiye da biyan shawarwarin telemedicine.
Cututtukan da ke shafar fatar hanci a cikin tsofaffi, kamar Basal cell carcinoma, ana yawan gano su. Hanci wuri ne na yau da kullun da ke faruwa ga irin wannan nau'in kansar fata.
Basal cell carcinoma na iya kasancewa tare da iyakoki marasa daidaituwa da ulcer.
Ana iya kuskure Basal cell carcinoma da wart.
relevance score : -100.0%
ReferencesBasal cell carcinoma (BCC) shine mafi yawan nau’in ciwon daji na fata. Hasken rana ne babban dalilin. Kusan dukkan lamuran BCC suna nuna siginar bushiya a binciken kwayoyin halitta. Ana samun jiyya daban‑daban, kuma an zaɓa su bisa ga haɗarin sake dawowa, mahimmancin adana nama, fifikon haƙuri, da girman cuta.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
Basal cell carcinomas sune nau'in ciwon daji na fata da aka fi gani a manya masu shekaru 50 da sama. Adadin su na karuwa a duniya, musamman saboda fallasa hasken rana. Wasu yanayi na kwayoyin halitta na iya sa mutane su yi saurin kamuwa da waɗannan cututtukan daji tun suna ƙanana. Basal cell carcinomas na iya bambanta da tsanani, daga ƙananan ƙwayoyin da za a iya magance su cikin sauƙi ko na nodular zuwa manyan waɗanda ke buƙatar tattaunawa a cikin ƙungiyoyin likitoci na musamman. Hasashen ya dogara ne da yuwuwar dawowar ciwon daji ko ikonsa na lalata nama da ke kusa. Tiyata shine maganin da aka fi amfani da shi a mafi yawan lokuta, yana ba da damar cire cutar da ƙananan damar sake dawowa. Hanyoyin magani masu ƙanƙanta na iya magance cututtuka masu tsanani.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
Babban magani na BCC shine tiyata. Don babban haɗari ko maimaita BCC, musamman a wurare masu mahimmanci, ana ba da shawarar tiyata mai sarrafa micrographically. Marasa lafiya masu ƙarancin haɗari na BCC na iya la'akari da jiyya na zahiri ko hanyoyin lalata. Photodynamic therapy yana aiki da kyau don nodular BCCs masu haɗari sama da ƙasa. Don BCC mai ci gaba a cikin gida ko mai tsauri, ana ba da shawarar masu hana Hedgehog (vismodegib, sonidegib). Idan cutar ta ci gaba ko marar haƙuri ga masu hana Hedgehog, ana iya ɗaukar immunotherapy tare da anti‑PD1 antibody (cemiplimab). Radiotherapy wani zaɓi ne mai kyau ga marasa lafiya waɗanda ba za su iya yin tiyata ba, musamman ma tsofaffi marasa lafiya. Ana iya la'akari da Electrochemotherapy idan tiyata ko radiotherapy ba zaɓi ba ne.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.
Abubuwan haɗari sun haɗa da haskakawa ga hasken ultraviolet, farfadowa na radiation, tsawon lokaci na ƙ exposure ga arsenic, da rashin aikin tsarin rigakafi (misali dasa gabobin jiki). Fitar da hasken UV a lokacin ƙuruciya yana da illa sosai.
Bayan ganewar asali ta biopsy, magani yawanci yana kan cirewa. Wannan na iya zama cirewa mai sauƙi idan ciwon daji ƙanana; idan ba ƙanana ba, ana ba da shawarar tiyata ta Mohs gabaɗaya.
Basal cell carcinoma yana da aƙalla kashi 32% na duk cututtukan daji a duniya. Na ciwon daji na fata ban da melanoma, kusan kashi 80% na ciwon daji na basal‑cell. A Amurka, kusan kashi 35% na maza masu fata farare da kashi 25% na mata masu fata farare suna fama da ciwon sankara na basal cell a wani lokaci a rayuwarsu.
○ Diagnosis da Magani
#Dermoscopy
#Skin biopsy
#Mohs surgery